Price movement over the last 24 hours
AbbVie Inc vs Dow Jones Industrial Average ETF — how do they compare? AbbVie Inc trades at $253.61 (market cap $449.91B), while Dow Jones Industrial Average ETF trades at $522.84. The key difference: AbbVie Inc pays a 2.72% dividend while Dow Jones Industrial Average ETF pays none. Which is the better fit depends on your goals.
| ABBV | DIA | |
|---|---|---|
Market Cap | $449.91B | — |
Sector | Health | — |
52-Week High | $261.07 | $530.02 |
52-Week Low | $184.85 | $435.72 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | — |
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $253.61, down 0.45% on the day, with strong technical momentum showing bullish moving averages and key support at $253. The company reported Q1 2026 EPS of $2.65, beating expectations, while revenue growth is supported by Skyrizi and Rinvoq offsetting Humira declines. Analysts maintain a bullish consensus with 68% buy ratings and a $266.33 price target, representing 5% upside potential.
The outlook remains positive with robust immunology portfolio performance and dividend growth, though risks include patent cliffs in the 2030s and competitive pressures. Current valuation metrics appear elevated with P/E at 124.83, requiring sustained earnings growth to justify premium multiples. The stock offers income appeal with consistent dividend payments while navigating portfolio transition.
DIA (SPDR Dow Jones Industrial Average ETF Trust) trades at $530.02, up 0.41% with a bullish technical signal from moving averages. The ETF tracks the Dow Jones Industrial Average, which recently surpassed 53,000 for the first time, driven by financials and tech exposure. Recent dividend distributions and strong institutional interest support the positive momentum, though oscillators indicate some overbought conditions with RSI levels above 70.
Outlook remains favorable given the Dow's 8% YTD gain and historical 13.3% average annual returns. Key risks include election-year volatility and potential Fed policy shifts under new Chair Kevin Warsh. Investors benefit from blue-chip diversification, but should monitor technical resistance near $533 and broader market sentiment for sustained upside.
Trailing returns across standard periods
Latest headlines on both assets
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →The ETF is designed to track the performance of the securities and the stocks in the Dow Jones Industrial Average Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on DIA →